AxioMed Spine
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$2.8m | Series A | ||
$18.0m | Series B | ||
N/A | $6.4m | Series C | |
N/A | $9.5m | Early VC | |
N/A | $15.0m | Series D | |
N/A | $500k | Grant | |
N/A | $5.0m | Series D | |
$3.6m | Series D | ||
N/A | $1.1m | Debt | |
N/A | $1.0m | Debt | |
* | N/A | $12.0m | Late VC |
Total Funding | AUD113m |
Related Content
Recent News about AxioMed Spine
EditAxiomed is a pioneering company in the medical device industry, specializing in next-generation total disc replacement solutions. The company focuses on developing innovative, one-piece disc replacement devices designed to provide both flexibility and support, thereby facilitating pain relief and the restoration of normal spinal function for patients suffering from degenerative disc disease. Axiomed serves a diverse range of clients, including healthcare providers, hospitals, and clinics that treat spinal conditions. Operating in the global medical device market, Axiomed's business model revolves around the research, development, and commercialization of advanced spinal care technologies. The company generates revenue through the sale of its proprietary disc replacement devices and related services. By leveraging cutting-edge technology and a patient-centric approach, Axiomed aims to redefine patient outcomes and improve the quality of life for individuals with spinal disorders.
Keywords: total disc replacement, spinal care, degenerative disc disease, pain relief, spinal function, medical device, healthcare, innovation, patient outcomes, technology.